

Annex 1

Claims

Claim 1: Use of an anti-PD-1 antibody which inhibits the interaction between PD-1 and PD-L1 and which inhibits the immunosuppressive signal of PD-1 for the manufacture of a medicament for cancer treatment.

Claim 2: The use according to claim 1, wherein the anti-PD-1 antibody is a human anti-PD-1 antibody.

Claim 3: Anti-PD-1 antibody which inhibits the interaction between PD-1 and PD-L1 and which inhibits the immunosuppressive signal of PD-1 for the use in cancer treatment.

Claim 4: Anti-PD-1 antibody for the use according to claim 3, wherein the anti-PD-1 antibody is a human anti-PD-1 antibody.

Annex 2

Claims

Claim 1: Use of an anti-PD-1 antibody which inhibits the immunosuppressive signal of PD-1 for the manufacture of a medicament for melanoma treatment.

Claim 2: The use according to claim 1, wherein the anti-PD-1 antibody is a human anti-PD-1 antibody.

Claim 3: Anti-PD-1 antibody which inhibits the immunosuppressive signal of PD-1 for the use in melanoma treatment.

Claim 4: Anti-PD-1 antibody for the use according to claim 3, wherein the anti-PD-1 antibody is a human anti-PD-1 antibody.

Annex 3

Claims

Claim 1: Use of an anti-PD-1 antibody which inhibits the interaction between PD-1 and PD-L1 and which inhibits the immunosuppressive signal of PD-1 for the manufacture of a medicament for melanoma treatment.

Claim 2: The use according to claim 1, wherein the anti-PD-1 antibody is a human anti-PD-1 antibody.

Claim 3: Anti-PD-1 antibody which inhibits the interaction between PD-1 and PD-L1 and which inhibits the immunosuppressive signal of PD-1 for the use in melanoma treatment.

Claim 4: Anti-PD-1 antibody for the use according to claim 3, wherein the anti-PD-1 antibody is a human anti-PD-1 antibody.